Methods for producing modified reverse transcriptases
US-2024124856-A1 · Apr 18, 2024 · US
Anti-inflammatory peptides and composition comprising the same
US2020140832A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2020140832-A1 |
| Application number | US-202016746018-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jan 17, 2020 |
| Priority date | Jul 20, 2012 |
| Publication date | May 7, 2020 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO:1 to SEQ ID NO:161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO:1 to SEQ ID NO:161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
First claim
Opening claim text (preview).
1 - 21 . (canceled) 22 . A method of treating or preventing inflammatory disease in a patient, comprising administering to the patient an isolated peptide having anti-inflammatory activity, wherein the peptide is 10 amino acids in length and has the amino acid sequence of SEQ ID NO: 4. 23 . The method according to claim 22 , wherein the inflammatory disease is selected from the group consisting of general or localized inflammatory disease; gastro-intestinal related diseases; dermal related diseases; vascular related disease; respiratory diseases; bone, joint, muscle, and connective tissue related diseases; urogenital disorders; central or peripheral nervous system related diseases; virus; and autoimmune diseases. 24 . The method according to claim 22 , wherein the peptide originates from human telomerase. 25 . The method according to claim 22 , wherein the peptide increases high mobility group protein box 1 (HMGB1) expression in a nucleus of a cell. 26 . The method according to claim 22 , wherein the peptide reduces the expression level of TNF-α. 27 . A method of treating or preventing skin inflammation comprising administering an isolated peptide having anti-inflammatory activity, wherein the peptide is 10 amino acids in length and has the amino acid sequence of SEQ ID NO: 4. 28 . The method according to claim 27 , wherein the peptide originates from human telomerase. 29 . The method according to claim 27 , wherein the peptide increases high mobility group protein box 1 (HMGB1) expression in a nucleus of a cell. 30 . The method according to claim 27 , wherein the peptide reduces the expression level of TNF-α.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2020140832A1 cover?
- The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO:1 to SEQ ID NO:161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising…
- Who is the assignee on this patent?
- Kim Sang Jae, Gemvax & Kael Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N9/1276. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu May 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).